ibi3002
mAbexperimentalBi-specific
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 26, 2024 (NCT06213844)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-4 receptor subunit alphaINHIBITOR
IL4R inhibitor
- Thymic stromal lymphopoietinINHIBITOR
TSLP inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07015762 | Phase 1 | Jul 14, 2025 | Innovent Biologics (Suzhou) Co. Ltd., Soochow University |
| NCT07015749 | Phase 1 | Jun 20, 2025 | Innovent Biologics (Suzhou) Co. Ltd., Soochow University |
| NCT06947408 | Phase 1 | May 14, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT06213844 | Phase 1 | Feb 26, 2024 | Innovent Biologics (Suzhou) Co. Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 4 | 2 | 1 | 2024 |
| Soochow University | Academic/Hospital | 2 | 2 | 1 | 2025 |
2 organizations
Page 1 / 1